Anavex Life Sciences Corp. (AVXL)

Market Cap	300.63M
Revenue (ttm)	n/a
Net Income (ttm)	-48.17M
Shares Out	85.89M
EPS (ttm)	-0.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,679,055
Open	3.540
Previous Close	3.580
Day's Range	3.440 - 3.640
52-Week Range	2.860 - 14.441
Beta	1.10
Analysts	Strong Buy
Price Target	33.00 (+842.86%)
Earnings Date	Dec 22, 2025

About AVXL

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept stud...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 42
• Stock Exchange: NASDAQ
• Ticker Symbol: AVXL
• Website: https://www.anavex.com

Analyst Summary

According to 3 analysts, the average rating for AVXL stock is "Strong Buy." The 12-month stock price target is $33.0, which is an increase of 842.86% from the latest price.

Price Target

$33.0

(842.86% upside)

Analyst Consensus: Strong Buy